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ABSTRACT 
THE EFFECT OF IN VIVO PBDE TREATMENT ON 
HEPATIC PHOSPHOENOLPYRUVATE CARBOXYKINASE (PEPCK) 
ENZYME KINETICS IN MALE WISTAR RATS 
by 
Jessica T. Nash 
University of New Hampshire, September 2011 
Polybrominated diphenyl ethers (PBDEs) are synthetic flame-retardant chemicals 
that enter the environment and mammalian body and may disrupt glucose metabolism. 
This study investigated the effect of PBDEs on a key gluconeogenic enzyme, 
phosphoenolpyruvate carboxykinase (PEPCK). Forty-eight male Wistar rats were 
gavaged with corn oil or corn oil containing 14 mg/kg DE-71 for 3, 14 or 28 days (N = 8 
per group). At each time point, fasting plasma glucose, insulin and C-peptide were 
measured and liver PEPCK enzyme activity was assayed. PBDEs significantly decreased 
PEPCK Vmax (u.mol/min/g liver weight) at 3 days by 26%; this reduction persisted 
through 28 days. PBDEs also reduced total PEPCK activity (jj.mol/min/liver) by 18% (3 
days) to 41% (28 days). Fasting plasma glucose levels remained unaffected by PBDE 
treatment. Findings demonstrate that PBDEs reduce hepatic PEPCK Vmax as early as 
three days of treatment; the implications for this reduction in glucose homeostasis remain 





This literature review is divided into five sections: chemical and physical 
properties of PBDEs including general characteristics, environmental presence and routes 
of exposure; metabolism of PBDEs including information about drug metabolizing 
enzymes; the metabolic effects of PBDEs including endocrine disruption and cytochrome 
P450 enzyme induction; the mechanism of PBDE action including PBDEs binding as a 
ligand to nuclear receptors; and phosphoenolpyruvate carboxykinase (PEPCK), 
xenobiotics and PBDEs including information about PEPCK activity following 
xenobiotic exposure. 
Chemical and Physical Properties of PBDEs 
Polybrominated diphenyl ethers (PBDEs) are a family of lipophilic, flame 
retardant chemicals introduced in the 1970's. PBDEs are used in consumer products 
including plastics, electronics, furniture and carpeting to slow the rate at which products 
burn. The structure of PBDEs is two phenyl rings attached by an ether bridge (Figure 1). 
The number of bromine atoms found on the phenyl rings can vary, generating 209 
possible congeners (Darnerud et al. 2001). The three most common industrial mixtures 
are penta-BDE, used mostly in furniture, and deca-BDE and octa-BDE, used mostly in 
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electronics (Hale et al. 2003; McDonald 2002). Penta-BDEs contain 3 to 6 bromine 
atoms and include the congeners BDE-47, -99, -100, -153, -154 and -85. Octa-BDEs 
contain 6 to 8 bromine atoms and include the congeners BDE-183 and -153. Deca-BDEs 
contain 8 to 10 bromine atoms and include the congener BDE-209 (Hale et al. 2003). 
Figure 1: General structure of PBDEs 
T n 2 
Figure 1: General structure of PBDEs. Location and number of bromine atoms 
theoretically forms 209 different congeners (Darnerud et al. 2001). 
PBDEs can be incorporated in consumer products in one of two ways: via a 
chemical reaction or as an additive. When the flame retardant is chemically reacted with 
a product, a covalent bond is formed between the flame retardant and product making the 
PBDEs less likely to leach into the environment. Additive PBDEs are only mixed with 
the polymer resin. Therefore, as products break down, additive PBDEs have the ability to 
leach into the environment because they are not chemically bound to the product 
(Darnerud et al. 2001; Kim et al. 2006; McDonald 2002). 
PBDEs are resistant to chemical and physical breakdown, therefore, once in the 
environment, they can bioaccumulate and even biomagnify within the food chain (Alaee 
and Wenning 2002; Costa et al. 2008; Hale et al. 2003). Originally, it was thought that 
deca-BDE was less bioaccumulative compared to other lower brominated congeners due 
to being fully brominated, poorly absorbed, rapidly excreted and having a high molecular 
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weight (McDonald 2002); (Huwe 2005; Norris et al. 1975). However, when exposed to 
ultraviolet light, deca-BDE can be converted to lower brominated congeners, increasing 
its bioaccumulative ability (Watanabe et al. 1987). 
Environmental Presence 
Since their introduction in the 1970s, PBDEs have been found in the environment 
and organisms worldwide including soil sediment, marine animals, fish-eating birds, 
human breast milk, serum and adipose tissue. In 1981, it was discovered that fish from 
the Viskan River in Sweden had PBDEs in their tissues (Andersson and Blomkviet 1981). 
In 1983, it was found that bird tissues from several U.S. locations and Ontario, Canada 
also contained PBDEs (Stafford 1983). PBDEs were found in fish-eating birds and 
marine animals in the Arctic region and in the same year, Watanabe et al., confirmed the 
same findings in the Pacific region (Jansson et al. 1987; Watanabe et al. 1987). More 
recently, PBDEs have been detected in human tissues including breast milk, serum and 
adipose, with levels in North Americans reportedly two to ten times higher than levels in 
Europeans and Asians (Dunn et al. 2010; Inoue et al. 2006; Lorber 2008; Petreas et al. 
2003; Schecter et al. 2003). 
Routes and Sources of Exposure 
There are three major routes of PBDE exposure: inhalation, dermal absorption 
and ingestion. Dust can serve as a PBDE source for all three routes. Indoor house dust 
was analyzed in cities in Canada, New Zealand, United Kingdom and United States and 
showed median concentrations of PBDEs ranging from 59 to 2,800 ng/g (Harrad et al. 
2008). A positive correlation was found between the levels of PBDEs in house dust and 
the levels of PBDEs in breast milk of mothers in Massachusetts (Wu et al. 2007). 
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Dust not only accounts for exposure via inhalation but also via dermal absorption 
(Lorber 2008). Blood samples from computer-dismantle workers in Sweden contained a 
variety of PBDEs. Congener BDE - 183 was the highest detected at 7.8 ng/g lipid weight 
whereas the control group had only 0.12 ng/g lipid weight (Sjodin et al. 1999). However, 
one in vitro study showed that only 3.13% of an applied dose of tetrabromodiphenyl ether 
was absorbed through human skin membranes and concluded that the risk of dermal 
absorption of PBDEs is lower than via inhalation and ingestion (Roper et al. 2006). 
Diet acts as another source of exposure to PBDEs. PBDEs have been found in a 
variety of marine animals consumed by humans, but they have also been detected in dairy 
products. A survey of various foods in the United States have shown a total concentration 
of greater than 6,000 pg/g in butter and over 900 pg/g and 1,000 pg/g in salmon and 
canned sardines, respectively. PBDE congener BDE-47 was detected in 30 of the 31 food 
samples tested and BDE-99 was detected in 28 of 31 food samples (Schecter et al. 2010). 
Breast milk has been analyzed in the U.S. with median levels ranging from 6.1 -
419 ng/g lipid (Schecter et al. 2003). Breast milk also serves as a source of PBDE 
exposure in infants. One case study analyzed serum levels of PBDEs in a family of four. 
The researchers found that the breast-fed infant had serum PBDE levels two to five times 
higher than his parents (Fischer et al. 2006). The sum of 6 PBDE congeners measured 
was 418 ng/g lipid weight (lw), while the toddler had 247 ng/g lw, mother 106 ng/g lw 
and the father 64 ng/g lw. The researchers concluded that the two to five-fold differences 
in PBDE levels seen in the younger children could be attributed to breast milk and dust as 
main sources of exposure for the infant and toddler, respectively. 
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Metabolism of PBDEs 
Once in the body, the target organs for PBDE toxicity are the liver, kidney and 
thyroid gland (Costa et al. 2008). One study sought to explore the level of toxicity of 
BDE-209 in neonatal rats. Sprague-Dawley rats were administered 100-600 mg of BDE-
209/kg body weight daily from postnatal day (PND) 10 to PND 46. Hypertrophy of the 
liver and thyroid gland, as absolute weight, were seen in the high dose group (Lee et al. 
2010). 
Another study investigated the toxicity of DE-71, a commercial mixture of mostly 
penta-BDE congeners. Male and female F344/N rats and B6C3F1 mice were 
administered a range of 0 - 500 mg/kg/day for 5 days/week for 13 weeks. The 
researchers found an increase in liver weights and liver lesions of rats receiving doses of 
5 mg/kg or higher and mice receiving 50 mg/kg or higher. They also saw hepatocyte 
hypertrophy in both rats and mice receiving doses of 50 mg/kg or higher (Dunnick and 
Nyska 2009). 
Metabolism studies of PBDEs have been mostly limited to rodents, von 
Meyerinck et al. (1990) administered a single dose of 300 mg/kg of Bromkal-70, a 
commercial mixture of penta-BDEs, to male and female rats. The highest concentration 
was seen in the adipose tissue four days after exposure (von Meyerinck et al. 1990). Orn 
and Klasson-Wehler demonstrated that after a single dose of 14.5 mg/kg body weight of 
14C-labeled BDE-47, 86% remained in the adipose, liver, lung, kidney, brain and plasma 
after 5 days while only 14% was excreted through the feces and <0.5% was excreted 
through the urine. The highest concentration was found to be in the adipose tissue (Orn 
and Klasson-Wehler 1998). 
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It has been shown PBDE metabolites can form within the body. The majority of 
metabolites found in the previous study were hydroxylated compounds: ortho-OH-
tetrabromoDE, weta-OH-tetrabromoDE and />ara-OH-tetrabromoDE (Orn and Klasson-
Wehler 1998). The purpose of adding an -OH group is to create a more hydrophilic 
compound making excretion of the toxin more feasible. 
Cytochrome P-450 
The detoxification of xenobiotics, specifically aromatic or aliphatic compounds 
such as PBDEs, occurs with the insertion of an oxygen atom (Poulos 1988, 2005). 
R - H + 0 2 + 2e " ^ R - O H 
A majority of hydroxylation occurs in the liver via drug metabolizing enzymes. One 
specific family of drug metabolizing enzymes is cytochrome P450 (CYP). There are 22 
known gene families of CYPs in mammals, denoted as CYPl, CYP2, CYP3 etc. and 
subfamilies denoted as CYP1A, CYP1B, CYP1C, etc. (Hakk and Letcher 2003; Nelson et 
al. 1996). The CYPl, CYP2 and CYP3 families are responsible for the majority of 
detoxification of xenobiotics (Nedelcheva and Gut 1994). CYPs are comprised of a single 
polypeptide chain containing a noncovalently bound heme. CYPs are between 45,000 and 
55,000 Daltons and are highly expressed in the liver and intestines (Poulos 1988, 2005). 
Metabolic Effects of PBDEs 
Many studies have demonstrated an increase of CYP gene expression and enzyme 
activity following exposure to PBDEs. It has been reported that the minimum dose of 
PBDEs necessary to induce CYPs ranges 3 - 1 0 mg/kg (Hakk and Letcher 2003). 
Sanders et al. (2005) administered treatments via gavage of DE - 71, PCBs and 
individual congeners of PBDEs in varying amounts of 0.005 - 150 mg/kg/day to male 
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F344 rats for 3 days. DE - 71 up-regulated gene expression of CYP1A1 by up to 3500-
fold at 150 mg/kg/day. When congeners BDE-47, -99 and -153 were administered 
between 57 and 150 mg/kg/day, CYP1A1 gene expression increased by 2.4, 8.1 and 19-
fold, respectively. Similar increase of gene expression was seen for CYP2B and CYP3A 
(Sanders et al. 2005). Exposure of human hepatocytes to BDE-99 and BDE-209 increased 
gene expression of CYP1A2 by up to 2 x 105 fold, and CYP3A4 up to 10 fold (Stapleton 
et al. 2009). A significant increase (fold increase was not reported) in protein expression 
of CYPl A2, CYP3A1 and CYP2B1 was also observed in a study that administered doses 
of 100, 300 or 600 mg/kg body weight of BDE-209 (Lee et al. 2010). 
PBDEs have been categorized as endocrine disrupting chemicals as they interfere 
with hormones including thyroid and the estrogen family. Hallgren and Darnerud (2002) 
found that free thyroxine (T4) was decreased by 61% compared to control rats following 
exposure to BDE-47 (Hallgren and Darnerud 2002). Zhou et al. (2001) found that 
weanling female rats, when exposed to varying commercial mixtures of PBDEs for 4 
days, had a dose-dependent decrease in total thyroxine (T4) (Zhou et al. 2001). The same 
researchers found that exposing pregnant female rats to the commercial penta mixture of 
PBDEs, DE-71, also decreased total T4 levels in the fetuses in a dose-dependent manner 
(Zhou et al. 2002). 
Studies have also demonstrated the ability of PBDEs to disrupt estrogen 
homeostasis. In one study, breast cancer cells and ovarian cancer cells were exposed to 
DE-71 and six synthesized hydroxylated PBDE metabolites. DE-71 failed to displace 
estradiol from the estrogen receptor alpha (ER-a), however, all six hydroxylated 
metabolites were able to displaced estradiol binding from ER-a (Mercado-Feliciano and 
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Bigsby 2008). Another study treated pregnant Wistar rats with 140 or 700 [xg/kg body of 
BDE-47 beginning on gestation day 6 through postnatal day 21. The researchers found a 
significant decrease in ovarian weight in the lower dose group and a decrease in serum 
estradiol concentrations in the higher dose group. (Talsness et al. 2008) 
PBDEs have also been implicated in disrupting adipocyte metabolism. Male 
Sprague-Dawley rats were gavaged 14 mg/kg of a penta-BDE mixture daily for 2 and 4 
weeks. Adipocytes were isolated and lipolysis and glucose oxidation was measured. 
Isoproterenol-induced lipolysis was 30% higher and insulin-stimulated glucose oxidation 
was 59% lower in cells of 4 week- treated rats compared to control (Hoppe and Carey 
2007). 
Mechanism of PBDE Action 
Similar to many other xenobiotics, PBDEs act by binding to nuclear receptors 
(NRs). NRs are a family of transcription factors that can be activated by a number of 
ligands including pharmaceutical drugs, endogenous compounds and environmental 
chemicals. Some examples of NRs include constitutive androstane receptor (CAR), 
pregnane X receptor (PXR) and aryl hydrocarbon receptor (AhR). Xenobiotics, such as 
PBDEs, will enter a cell either by passive diffusion or active transport and can bind to 
NRs in the cytosol (Figure 2). Once bound by a ligand, the nuclear receptor-xenobiotic 
compound will enter the nucleus. The nuclear receptor will form a heterodimer with other 
receptors, such as retinoid X receptor (RXR), and bind to a response element on the 
DNA, triggering gene transcription and, eventually, translation of the corresponding CYP 
enzyme (Hewitt et al. 2007; Tompkins and Wallace 2007). 
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Figure 2: Cell model of CYP Induction 
Figure 2: General induction process of the drug metabolizing enzymes, CYPs, via gene 
transcription following exposure to a xenobiotic. (Denoted in the figure as "xeno"; 
adapted from (Hewitt et al. 2007). 
PBDEs as a Ligand 
PBDEs have been confirmed as ligands and activators of PXR, but not for CAR 
or AhR (Sakai et al. 2009; Wahl et al. 2010). Pacyniak et al. (2007) used human HepG2 
cells and transfected them with a number of plasmids including cDNA for mouse PXR 
bound to luciferase vectors. Cells were exposed to PBDEs for 24-hours. Luciferase 
activity significantly increased in a dose-dependent response to varying PBDE congeners 
demonstrating that PBDEs bind as a ligand to PXR. 
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The researchers wanted to explore if there was a similar response in vivo and used 
two groups of mice, wild type and PXR knockout, to investigate this question. The mice 
were injected with a mixture of 100 mg/kg/day of BDE-47, -99, and -209 for 4 days. 
There was an increase in CYP3A and 2B RNA and protein by 2 to 2.5 fold in the wild 
type, as expected, and an increase, but to a lesser degree, of the same CYP RNA and 
protein in the PXR knockout mice. The authors suggested that there might be other ways 
in which PBDEs induce CYPs (Pacyniak et al. 2007). 
In a similar study, human HepG2 and rat hepatoma H4IIE cells were transfected 
with an XREM reporter gene (a plasmid that is transactivated by PXR) containing 
luciferase as the reporter. Cells were exposed to a technical mixture of pentaBDEs for 48 
hours. The pentaBDE mixtures increased CYP3A1 and CYP3A4 mRNA by 1 to 4 fold in 
both cell types (Fery et al. 2009), demonstrating that PBDEs act as a ligand for PXR in 
human and rat liver cells in vitro. 
PXR Crosstalks with Gluconeogenesis 
PXR has direct transcriptional regulation over drug metabolizing enzymes but can 
also crosstalk with other transcription factors to alter expression of other metabolic genes 
involved in gluconeogenesis (GNG) (Ihunnah et al. 2011). GNG is the conversion of 
substrates including lactate, glycerol and pyruvate, to glucose, as the brain needs a 
constant supply of glucose to sustain function. GNG occurs during fasted states such as 
overnight when no dietary glucose is being supplied. Consumption of a high-
carbohydrate diet will slow GNG to cessation until the next fasted state. GNG is a 
regulated process and the regulation is three-fold: via substrates, by hormones such as 
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insulin and glucagon and by key regulatory enzymes, one of which is 
phosphoenolpyruvate carboxykinase (PEPCK) (Harvey and Ferrier 2011). 
Studies have shown that activated PXR can repress specific genes found in the 
GNG pathway, including PEPCK. Zhou et al. (2008) used wild type mice or transgenic 
mice that expressed an activated form of PXR in the liver. In the transgenic mice, RNA 
expression of PEPCK was reduced compared to the wild type (Zhou et al. 2006). Bhalla 
et al. (2004) found similar results in vitro. HepG2 cells were transfected with human PXR 
vector and then exposed to 10 uM rifampicin, a known PXR ligand, or dimethyl 
sulfoxide (Me2SO) as control for 24 hours. RNA expression of PEPCK was decreased in 
the rifampicin-treated cells compared to cells treated with Me2SO (Bhalla et al. 2004). 
These results demonstrate that when PXR is activated, PEPCK gene expression is 
suppressed. 
PEPCK. Xenobiotics and PBDEs 
Phosphoenolpyruvate Carboxykinase (PEPCK) 
PEPCK converts oxaloacetate to phosphoenolpyruvate and uses guanosine 
triphosphate (GTP)- or inosine triphosphate (ITP)- as a co-substrate (Figure 3). PEPCK is 
present in the liver, kidney, lung, heart, small intestine and adipose tissue and resides in 
both the mitochondria and cytosol of most mammals, although subcellular distribution 
varies by species. For example, in humans, 60% of PEPCK is found in the mitochondria 
with 40% in the cytosol. In rats, only 10% is found in the mitochondria while 90% is in 
the cytosol (Hanson and Garber 1972; Hanson and Reshef 1997). 
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Cytosolic PEPCK is highly regulated by diet and hormones including thyroid 
hormone, glucagon, glucocorticoids and insulin. During fasting, activity of cytosolic 
PEPCK increases by two- to eight-fold while the mitochondrial isoform remains virtually 
Figure 3: Gluconeogenesis Pathway 
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Figure 3: The pathway of gluconeogenesis showing PEPCK (circled), dependent on 
GTP, to convert oxaloacetate to phosphoenolpyruvate (PEP) (King 2011). 
unaffected, suggesting distinct isoform regulation (Ballard and Hanson 1969; Hanson and 
Reshef 1997). In animals with predominant mitochondrial isoforms of PEPCK, 
oxaloacetate (OAA) that is generated in the mitochondria via pyruvate carboxylase can 
be converted to phosphoenolpyruvate (PEP). However, due to the poor permeability of 
OAA in the mitochondria, animals that have the dominant form of PEPCK located in the 
cytosol, must first convert OAA to malate and transport malate into the cytosol. Once in 
the cytosol, malate is oxidized to OAA by malate dehydrogenase (MDH) where the 
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cytosolic form of PEPCK can then convert OAA to PEP (Hanson and Reshef 1997). The 
cytosolic form of PEPCK in the rat liver consists of 621 amino acids, has a molecular 
weight of 69 kD (Beale et al. 1985) and a half-life of 6-8 hours (Ballard et al. 1974). 
Other Roles of PEPCK 
PEPCK is also present in nongluconeogenic tissues and, in the case of adipose 
tissue and small intestine, is proposed to aid in providing glycerol backbone for 
triglyceride synthesis via the process of glyceroneogenesis. (Hanson and Reshef 1997; 
Reshef et al. 1970) Another role of PEPCK is cataplerosis or removal of citric acid cycle 
anions. Hakimi et al. (2005) evaluated the metabolic consequences of deleting the 
cytosolic form of PEPCK (PEPCK-C) in the liver and kidney of mice in utero. [Fetal 
livers do not contain PEPCK, as glucose is provided by the mother, but it appears at birth 
corresponding to the needs of glucose production (Hanson and Reshef 1997)]. Mice were 
killed two or three days after birth. The PEPCK knockout mice did not gain weight one 
day after birth. Blood glucose levels in PEPCK knockout mice were 60% lower than 
controls. Lipid accumulated in the liver of the PEPCK knockout mice and the triglyceride 
level in the liver was twice the amount of controls. The same elevated level of 
triglycerides was also seen in the blood of PEPCK knockout mice. The blood 
concentration of (3-hydroxybutyrate, a ketone body, was three times higher than control, 
and the levels of malate and lactate were 10 and 2.5 times higher, respectively, than 
control (Hakimi et al. 2005). These results show the importance of PEPCK, not only in 
the process of GNG, but also in maintaining homeostasis of energy metabolism. 
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Regulation of PEPCK 
The gene for PEPCK-C is regulated at the transcriptional level via induction and 
repression. During times of starvation, PEPCK-C is induced and consumption of a high 
carbohydrate diet will reduce PEPCK synthesis. Glucagon, a hormone released during 
times of low blood sugar, and thyroid hormone both increase PEPCK-C synthesis while 
insulin, released during times of high blood sugar, inhibits PEPCK-C synthesis (Ballard 
and Hanson 1967; Gurney et al. 1994; Hanson and Reshef 1997). 
The mechanism of glucagon induction involves glucagon binding to its surface 
receptor, which stimulates Gs-protein. Stimulated G-protein will then stimulate adenylyl 
cyclase causing an increase in cAMP levels. The increase in cAMP levels causes a 
phosphorylation of protein kinase A (PKA). Activated PKA then phosphorylates cAMP 
regulatory element binding protein (CREB), which binds to cAMP response element-1 
(CRE-1). CRE-1 is located in Region 1 of the PEPCK-C gene promoter and is in close 
proximity to the start location of transcription (Roesler et al. 1988, 1989; Yabaluri and 
Bashyam 2010). If PEPCK mRNA is not translated, existing PEPCK mRNA will be 
degraded with a half-life of about 40 minutes (Cimbala et al. 1982). However, the 
presence of cAMP stabilizes PEPCK mRNA and extends the half-life to 140-250 minutes 
(Hod and Hanson 1988). In contrast, glucocorticoids and thyroid hormone diffuse 
through the plasma membrane and bind to receptors located in the cytosol. The occupied 
receptors translocate into the nucleus and bind to glucocorticoid response elements 
(GRE1 or -2) and a thyroid response element (TRE) on the PEPCK gene promoter, 
respectively (Yabaluri and Bashyam 2010), to promote PEPCK transcription. 
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Insulin acts in an opposing mechanism to glucagon. The presence of insulin 
decreases the levels of cAMP causing PKA to remain inactive and does not 
phosphorylate CREB (Harvey and Ferrier 2011). Insulin can also phosphorylate a 
forkhead transcription factor (FOXOl) that normally is responsible for activating the 
PEPCK gene. Phosphorylation of FOXOl renders it inactive by decreasing FOXOl's 
binding affinity to the insulin response sequence (IRS) (O'Brien et al. 1995; Zhang et al. 
2006), removing PEPCK gene activation. 
Xenobiotic Effects on GNG and PEPCK 
The effect of PBDE exposure in vivo and in vitro on GNG and PEPCK is 
currently unknown. However, studies using other xenobiotic compounds have examined 
effects on GNG and PEPCK. Male Wistar rats were administered an oral dose of 100 
mg/kg/day of Phenobarbital, a pharmaceutical drug used to treat epilepsy and diabetes, 
for 15 days. Hepatocytes were isolated and exposed to gluconeogenesis precursors 
lactate/pyruvate, alanine, glycerol and glutamine. Glucose production was inhibited by 
50% and PEPCK activity was also inhibited by 50% (Argaud et al. 1991). Chauvin et al. 
(1996) found hepatic PEPCK enzyme kinetics from Phenobarbital-treated rats, 
lOOmg/kg/day for 14 days was altered: Vmax and Km was reduced by about 50% and 
30%, respectively. The researchers also determined the effect of Phenobarbital treatment 
on PEPCK activity was post-translational as PEPCK protein and mRNA did not decrease 
(Chauvin et al. 1996). 
Viluksela et al. (1999) administered oral dosages of 2,3,7,8-tetrachlorodibenzo-/?-
dioxin (TCDD), a compound present in Agent Orange, ranging from 50 to 9600 
ug/kg/day to male and female Han/Wistar rats for 10 days. PEPCK activity decreased in 
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a dose-dependent manner with the highest dose of TCDD reducing maximal activity by 
about 50% in males and 25% in females. Plasma glucose levels were also slightly 
decreased compared to controls (Viluksela et al. 1999), suggesting that TCDD represses 
PEPCK activity and, as a result, alters glucose homeostasis. 
Vijayan et al. (2006) used Anadromous arctic char, a fish that resides in Arctic 
bodies of water, and administered 0 or 100 mg/kg/day of Aroclor 1254, a commercial 
polychlorinated biphenyl (PCB) mixture, for 4 months. The researchers treated two 
groups of fish but fasted one group to mimic the natural fasting pattern seen during the 
winter months and continuously fed another group for comparison. Results showed a 
55% reduction in plasma glucose and a 66% reduction of PEPCK activity in the 100 
mg/kg fasted group compared to both the 0 mg/kg fasted group and the 100 mg/kg fed 
group (Vijayan et al. 2006). These data suggest that, in fish, PCB not only reduces 
PEPCK activity but also inhibits glucose production in the fasted, but not fed, state. 
Summary 
PBDE treatment has been shown to increase hepatic CYP RNA, protein and 
activity. PBDEs also act as a ligand and activator of the nuclear receptor, PXR. Animal 
models with activated PXR have shown a decrease in hepatic PEPCK mRNA. It has been 
established that exposure of animals to certain xenobiotics reduces activity of PEPCK, 
the key enzyme found in the gluconeogenesis pathway. The effect of PBDE exposure of 
rats on hepatic PEPCK activity is unknown. 
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Hypothesis 
The purpose of this study was to determine the effect of in vivo PBDE treatment 
of rats on hepatic PEPCK activity and in vivo glucose homeostasis: it tested the 
hypothesis that hepatic PEPCK activity is reduced by in vivo PBDE treatment of rats. 
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CHAPTER II 
MATERIALS AND METHODS 
Animals 
Forty-eight male Wistar rats, (Charles River Laboratory, Wilmington, MA) were 
used for this study. All rats weighed between 75-100 grams upon arrival. The rats were 
housed under controlled atmosphere and a 12- hour light/dark cycle. They were fed 
standard chow and water ad libitum. The University of New Hampshire's Animal Care 
and Use Committee approved all procedures, #110406. 
Treatment 
The rats were allowed to adjust to their new habitat for five days prior to the start 
of treatment. The rats were randomly assigned to two different gavage treatments: 14 mg 
PBDE / kg body weight / day (n = 24) or corn oil control (n = 24). Rats were gavaged 
daily, generally between 8 and 9 am. Initial body weights were obtained at the onset of 
treatment and body weight was recorded three times per week. Rats were euthanized after 
a 16 - hour fast at 3, 14 and 28 days of treatment (n = 8), using carbon dioxide gas. (Gas 
was allowed to fill the chamber for 90 seconds, followed by 90 seconds of no gas.) 
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Solutions 
PBDE Gavaging Solution 
• Two grams of DE - 71, a commercialized mixture of penta - PBDEs (Great 
Lakes Chemical Corporation, West Lafayette, IN through a generous gift from Dr. 
David Szabo) was removed from the original glass vial via a small metal spatula, 
dissolved into 2400 ul of hexane in a secondary glass vial and vigorously mixed. 
The mixture was placed in a 37°C water bath and stirred with a glass rod until 
PBDEs were completely dissolved. The mixture was poured into an amber glass 
bottle containing 60 ml of corn oil. An additional 51 ml of corn oil were added 
and the bottle was vortexed for 30-60 seconds to mix contents thoroughly. The 
hexane was evaporated under the hood using compressed nitrogen for 5 - 10 
hours. The solution was stored in an amber bottle at room temperature. 
Corn Oil Gavaging Solution 
• Hexane, 2400 ul, was added to 111 ml of corn oil in an amber bottle. The vial was 
vortexed for 30-60 seconds to mix contents thoroughly. The hexane was then 
evaporated using compressed nitrogen under the hood for 5 - 10 hours. The 
solution was stored in an amber bottle at room temperature. 
Preparation of Blood and Liver Samples 
Blood 
Rats were removed from the euthanasia chamber, the abdominal cavity was 
spread and a lateral incision was made to expose the internal organs. The diaphragm was 
then cut to expose the heart. Approximately 5 ml of blood was obtained via cardiac 
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puncture using a 0.2% EDTA-rinsed 18G-1.5" needle attached to a 5 ml syringe. Blood 
was transferred to a 6 ml EDTA - treated tube (Thermo Fisher Scientific, Waltham, MA) 
and kept on ice until it was transported back to the lab. Once in the lab, the collected 
blood was centrifuged at 3000 rpm for 15 minutes at 4°C in an IEC - Centra8R 
centrifuge. Approximately 1-2.5 ml of plasma was removed, aliquoted into cryovials in 
the amount of 250 - 400 ul, frozen and stored at -80°C. 
Liver 
The liver was removed, weighed, cut into approximately two-gram portions, flash 
frozen in liquid nitrogen, wrapped in aluminum foil and stored at -80°C. 
Preparation of Liver Cytosol Fraction 
Liver cytosol fraction was prepared, with modifications, as described by Chauvin 
et al. (1996). Liver was thawed, weighed (approx. 2 g), minced with scissors and placed 
in nine volumes of working homogenizing solution (refer to Solutions). Tissue was then 
homogenized for 15 seconds using a Powerstat® polytron (Thermo Fisher Scientific, 
Waltham, MA) at a setting of 60. 
Homogenized liver was centrifuged at 3116.425 x g (5000 rpm) for 15 minutes at 
4°C in a Sorvall Evolution RC centrifuge. The supernatant was removed and centrifuged 
at 59466 x g (30000 rpm) for 60 minutes at 4°C in a Beckman L8-80 ultracentrifuge. 
Supernatant was removed, placed on ice and used for PEPCK enzyme-coupled assay 
analysis. Total protein concentration of the supernatant was measured via a commercial 
DC protein assay (BioRad, Hercules, CA). 
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Solutions 
Stock Solution of 0.5 M Potassium Phosphate, pH 7.0 
• The solution was made by placing 13.609 g of potassium phosphate (FW: 136.09) 
into 150 ml ddH20. The pH was adjusted to 7 with NaOH and the final volume 
was brought to 200 ml. Solution was stirred and stored at 4°C. 
Stock Solution of 50 mM PMSF 
• The solution was made by placing 0.1742 g of PMSF (FW: 174.19) in 100% 
ethanol with the final volume being brought to 20 ml. Solution was vortexed until 
particles dissolved and stored at 4°C. 
Stock Solution of 50 mM DTT 
• The solution was made by placing 0.154 g of DTT (FW: 154.25) in ddH20 with 
the final volume being brought to 20 ml. Solution was stirred and stored at 4°C. 
Stock Solution of 20 mM EDTA 
• The solution was prepared by placed 0.7368 g of EDTA (FW: 368.4) into ddH20 
with the final volume being brought to 100 ml. The solution was stirred and 
stored at 4°C. 
Stock Solution of 0.5 mM Leupeptin 
• The solution was prepared by placing 0.0021 g of leupeptin (FW: 426.6) into 
ddH20 with the final volume being brought to 10 ml. The solution was stirred, 
aliquoted into cryovials (100 \x\) and frozen at -20°C. 
Working Homogenizing Solution 
• Twelve milliliters of 0.5 M Potassium Phosphate stock solution, 1.2 ml of 50 mM 
PMSF stock solution, 1.2 ml of 50 mM DTT stock solution, 3 ml of 20 mM 
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EDTA stock solution and 120 ul of 0.5 mM leupeptin stock solution were mixed 
with the final volume being brought to 60 ml with ddH20. The final concentration 
of the working homogenizing solution consisted of 0.1 M potassium phosphate, 
pH 7; 1 mM PMSF; 1 mM DTT; 1 mM EDTA; and 1 uM leupeptin. 
Analysis of Blood and Liver 
Blood Analysis 
Blood was analyzed for fasting glucose, insulin and C-peptide. Fasting glucose 
was measured using a commercial glucose oxidase kit (Sigma-Aldrich, St. Louis, MO). 
Insulin and C-peptide were measured using commercial ELISA and RIA kits, 
respectively (Millipore, Billerica, MA). 
Liver Cytosol Fraction 
The liver cytosol was used for a Phosphoenolpyruvate Carboxykinase (PEPCK) 
enzyme-coupled assay and was performed, with modifications, as described by Chauvin 
et al. (1996). The enzyme-coupled assay utilizes malate dehydrogenase (MDH) to 
convert malate to oxaloacetate (OAA). PEPCK then converts OAA to 
phosphoenolpyruvate (PEP). MDH requires nicotinamide adenine dinucleotide (NAD+) 
as a coenzyme resulting in the generation of the reduced form of nicotinamide adenine 
dinucleotide (NADH). (Figure 4) The presence of NADH can then be measured 
spectrophotometrically at 340 nm. 
A 3-ml acrylic cuvette contained the following: 12.5 mM Tris, pH 8.0; 0.75 mM 
MnCl2; 1 mM NAD+; 6 U of malate dehydrogenase and varying amounts of malate (0, 
0.125, 0.25, 0.375, 0.5, 1, 2, 4 and 8 mM), as shown in Table 1. The mixture was allowed 
to equilibrate in a 37°C water bath for three minutes. 
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Figure 4: PEPCK enzyme-coupled assay 
MDH PEPCK 
malate <4 ^ OAA ^ PEP 
NAD+ NADH GTP GDP 
Figure 4: The PEPCK enzyme-coupled assay. The generation of OAA 
from malate via MDH provides PEPCK with the necessary substrate to synthesize PEP. 
One hundred and twenty ul of liver cytosol fraction was added and allowed to equilibrate 
in a 37°C water bath for an additional one minute. To start the reaction, 1 mM GTP was 
added with a final volume of 2 ml. NADH formation was measured 
spectrophotometrically at 340 nm. The assay was performed in duplicate for each amount 
of malate. The assay was programmed to run for 15 seconds / cycle for an average of 4 
minutes (-16 cycles). 
Beer's law was used to determine the activity (velocity, v) of PEPCK (A= Ebc). 
'A' is the change in OD, 'E' is the extinction coefficient of NADH (6200 L/ (mol x cm), 
'b' is the path length of the cuvette (1 cm) and 'c' is the concentration (mol/L). The 
following equations were used to normalize for the amount of protein (umol / min / mg 
protein) and the amount of liver (umol / min / g wet weight liver). 
Protein: 
r (Average A/min) -, 
/ \ x106umol/mol x 0.002 L 
L V 6200 L/(mol x cm) / J 




[ (Average A/mirt) -, 
/ \
 X106umol/mol x 0.002 L 
V 6200 L/(mol x cm) / J 
Ys [liver (g) / buffer (ml)] \
 x 1 2o ul "l 
L 1000ul/ml J 
Solutions 
Stock Solution of 100 mM Tris. pH 8.0 
• The solution was prepared by placing 1.211 g of Tris (FW: 121.1) in 80 ml of 
ddH20. pH was adjusted to 8.0 with HC1 and the final volume was brought to 100 
ml. The solution was stored at 4°C. 
Stock Solution of 5 mM MnCl? 
• The solution was prepared by placing 0.0989 g of MnCl2 (FW: 197.9) in ddH20 
with the final volume being brought to 100 ml. The solution was stored at 4°C. 
Stock Solution of 10 mM NAD+ 
• The solution was prepared by placing 0.1326 g of NAD+ (FW: 663.4) in 20 ml of 
ddH20. The solution was mixed thoroughly and then aliquoted into cryovials in 
the amount of 500 \i\ and stored at -20°C. 
Stock Solution of 1:500 dilution of MDH (Sigma Aldrich. 2.2 me/ml) 
• Ten \x\ of MDH was placed into 490 \K\ of 0.9% NaCl. Mixture was made fresh 
for each assay and kept on ice for the duration of the experiment. 
0.9% NaCl: 
• The solution was prepared by dissolving 0.9 grams of NaCl in ddH20 and the 
volume was brought to 100 ml. The solution was stored at 4°C. 
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Stock Solution of 10 mM Malate 
• The solution was prepared by placing 0.0356 g of malate (FW: 178.05) in 20 ml 
of ddH20. The solution was stored at 4°C. 
Stock Solution of 20 mM Malate 
• The solution was prepared by placing 0.0712 g of malate (FW: 178.05) in 20 ml 
of ddH20. The solution was stored at 4°C. 
Stock Solution of 10 mM GTP 
• The solution was prepared by placing 0.1046 g of GTP (FW: 523.2) in 20 ml of 
ddH20. The solution was mixed thoroughly and then aliquoted into cryovials in 
the amount of 500 ul and stored at -20°C. 
Table 1: Assay Cuvette 
0 mM malate 
12.5 mM Tris 
0.75 mM MnCl2 
1 mM NAD+ 
1:500 MDH 
1 mM GTP 











8 mM malate 
100 mM Tris 















4 mM malate 
100 mM Tris 















Table 1: Examples of solution amounts added to assay cuvette. Water amount changed 
with corresponding malate amount. A 20 mM concentration of malate was used for 8 mM 
cuvette in order to maintain a final volume of 2 ml. 
Statistics 
Statistical analysis was performed on JMP 8.0 software. A two-way ANOVA -
general linear model analysis was performed using PBDE treatment and time as main 
effects and PBDE treatment x time as a covariate. Significance was set as p < 0.05. 
Outliers were excluded using a Q-test (Fritz and Schenk 1969). 
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CHAPTER III 
THE EFFECT OF IN VIVO PBDE TREATMENT ON 
HEPATIC PHOSPHOENOLPYRUVATE CARBOXYKINASE 
ENZYME KINETICS 
IN MALE WISTAR RATS 
INTRODUCTION 
Phosphoenolpyruvate carboxykinase (PEPCK) is a key regulatory enzyme in 
gluconeogenesis (GNG) that converts oxaloacetate to phosphoenolpyruvate and is 
dependent on guanosine triphosphate (GTP)- or inosine triphosphate (ITP)-. PEPCK is 
present in the liver, kidney, lung, heart, small intestine and adipose tissue and resides in 
both the mitochondria and cytosol of most mammals, although its distribution varies. For 
example, in humans, 60% of PEPCK is found in the mitochondria with 40% in the 
cytosol. In rats, only 10% is found in the mitochondria while 90% is in the cytosol 
(Hanson and Garber 1972; Hanson and Reshef 1997) 
Cytosolic PEPCK (PEPCK-C) is highly regulated by diet and hormones including 
thyroid, glucagon, glucocorticoids and insulin. (Ballard and Hanson 1969; Hanson and 
Reshef 1997) The gene for PEPCK-C is regulated at the transcriptional level via 
induction and repression. During times of starvation, PEPCK-C is induced and 
consumption of a high carbohydrate diet will reduce synthesis. Glucagon, a hormone 
released during times of low blood sugar, and thyroid hormone both increase PEPCK-C 
26 
synthesis while insulin, released during times of high blood sugar, inhibits gene synthesis 
(Ballard and Hanson 1967; Gurney et al. 1994; Hanson and Reshef 1997). 
Studies have been conducted examining effects of xenobiotics on hepatic GNG 
and PEPCK. Phenobarbital (PB) exposure of rats inhibited hepatocyte glucose production 
and PEPCK activity by 50% (Argaud et al. 1991). Chauvin et al. (1996) found PEPCK 
enzyme kinetics from PB-treated rats decreased Vmax and Km by about 50% and 30%, 
respectively (Chauvin et al. 1996). Following exposure to 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD), male rats had a 50% decrease of PEPCK activity at the highest dose and 
female rats had a 25% decrease. Plasma glucose levels were also slightly decreased 
compared to controls (Viluksela et al. 1999). A 55% reduction of plasma glucose and a 
66% reduction of PEPCK activity were also observed in fish following exposure to a 
polychlorinated biphenyl mixture (Vijayan et al. 2006). 
Another class of xenobiotic is polybrominated diphenyl ethers (PBDEs). PBDEs 
are a family of lipophilic, flame retardant chemicals introduced in the 1970's. PBDEs are 
used in consumer products including plastics, electronics, furniture and carpeting to slow 
the rate at which products burn (Darnerud et al. 2001). PBDEs are only mixed with the 
polymer resin. Therefore, as products break down, PBDEs have the ability to leach into 
the environment because they are not chemically bound to the product (Darnerud et al. 
2001; Kim et al. 2006; McDonald 2002). Since PBDEs are resistant to chemical and 
physical breakdown, they can bioaccumulate in the environment and even biomagnify 
within the food chain (Alaee and Wenning 2002; Costa et al. 2008; Hale et al. 2003). 
PBDEs have been found in soil sediment, marine animals, fish-eating birds, dairy 
products, and human breast milk, serum and adipose tissue (Andersson and Blomkviet 
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1981; Dunn et al. 2010; Inoue et al. 2006; Jansson et al. 1987; Lorber 2008; Petreas et al. 
2003; Schecter et al. 2010; Schecter et al. 2003; Stafford 1983; Watanabe et al. 1987). 
Moreover, PBDEs are classified as an endocrine disrupting chemical as they have been 
shown to alter thyroid and estrogen family hormone homeostasis (Hallgren and Darnerud 
2002; Zhou et al. 2001; Zhou et al. 2002). A disruption in insulin stimulated glucose 
metabolism was also observed in adipocytes isolated from in vivo PBDE treatment of rats 
(Hoppe and Carey 2007). The effect of PBDE treatment on PEPCK activity is unknown. 
The purpose of this study was to determine the effect of in vivo PBDE treatment 
of rats on hepatic PEPCK activity and fasting plasma glucose and insulin. Our hypothesis 
was that hepatic PEPCK activity is reduced by in vivo PBDE treatment of rats. 
28 
MATERIALS AND METHODS 
Animals 
Forty-eight male Wistar rats, (Charles River Laboratory, Wilmington, MA) were 
used for this study. All rats weighed between 75-100 grams upon arrival. The rats were 
housed under controlled pressure and a 12- hour light/dark cycle. They were fed standard 
chow and water ad libitum. The University of New Hampshire's Animal Care and Use 
Committee approved all procedures, #110406. 
Treatment 
The rats were allowed to adjust to their new habitat for five days prior to the start 
of treatment. The rats were randomly assigned to two different gavage treatments: 14 mg 
PBDE / kg body weight / day (n = 24) or corn oil control (n = 24). Rats were gavaged 
daily, generally between 8 and 9 am. Initial body weights were obtained at the onset of 
treatment and body weight was recorded three times per week. Rats were euthanized after 
a 16 - hour fast at 3, 14 and 28 days of treatment (n = 8), using carbon dioxide gas. 
Preparation of Blood and Liver Samples 
Blood 
Approximately 5 ml of blood was obtained via cardiac puncture using a 0.2% 
EDTA rinsed 18G-1.5" needle and a 5 ml syringe. Blood was transferred to a 6 ml EDTA 
- treated tube (Thermo Fisher Scientific, Waltham, MA) and kept on ice until it was 
transported back to the lab. Once in the lab, the collected blood was centrifuged at 3000 
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rpm for 15 minutes at 4°C in an IEC - Centra8R centrifuge. Approximately 1-2.5 ml of 
plasma was removed, aliquoted into cryovials in the amount of 250 - 400 ul, frozen and 
stored at -80°C. 
Liver 
The liver was removed, weighed, cut into approximately two-gram portions, flash 
frozen in liquid nitrogen, wrapped in aluminum foil and stored at -80°C. 
Preparation of Liver Cytosol Fraction 
Liver cytosol fraction was prepared as described by Chauvin et al. (1996) with the 
following additional details. A liver portion was thawed, weighed (approx. 2 g), minced 
with scissors and placed in nine volumes of working homogenizing solution. Tissue was 
then homogenized for 15 seconds using a Powerstat® polytron (Thermo Fisher 
Scientific, Waltham, MA) at a setting of 60. 
Analysis of Blood and Liver 
Blood Analysis 
Blood was analyzed for fasting glucose (glucose oxidase kit, Sigma-Aldrich); 
insulin and C-peptide (ELISA and RIA kits, respectively, Millipore), according to 
manufacturer' s instructions. 
Liver Cytosol Fraction 
The liver cytosol was used for a phosphoenolpyruvate carboxykinase (PEPCK) 
enzyme-coupled assay, which was performed with modifications, as described by 
Chauvin et al. (1996). The enzyme-coupled assay utilizes malate dehydrogenase (MDH) 
to convert malate to oxaloacetate (OAA). PEPCK then converts OAA to 
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phosphoenolpyruvate (PEP). MDH requires nicotinamide adenine dinucleotide (NAD ) 
as a coenzyme resulting in the generation of the reduced form of nicotinamide adenine 
dinucleotide (NADH), which can be measured spectrophotometrically at 340 nm. 
A 3-ml acrylic cuvette contained the following with a final volume of 2 ml: 12.5 
mM Tris, pH 8.0; 0.75 mM MnCl2; 1 mM NAD+; 6 U of malate dehydrogenase and 
varying concentrations of malate ( 0 - 8 mM). The mixture was allowed to equilibrate in a 
37°C water bath for three minutes. One hundred and twenty ul of liver cytosol fraction 
was added and allowed to equilibrate in a 37° C water bath for an additional one minute. 
To start the reaction, 1 mM GTP was added. NADH formation was measured 
spectrophotometrically at 340 nm at 23°C. The assay was performed in duplicate for each 
concentration of malate. 
In order to normalize Vmax for mg of protein, total protein concentration of the 
cytosol was measured via a commercial DC protein assay (BioRad). 
Statistics 
Statistical analysis was performed on JMP 8.0 software. A two-way ANOVA -
general linear model analysis was performed using PBDE treatment and time as main 
effects and PBDE treatment x time as a covariate. Significance was set as p < 0.05. 




Final body weight, weight gain over the treatment period, final liver weight and 
liver as a percent of body weight are represented as mean ± SEM at days 3, 14 and 28 
(Table 2). There was a significant effect of time (p < 0.05) on final body weight and the 
effect of PBDE treatment on final body weight was approaching significance (p = 0.07). 
There was a significant effect of time (p < 0.05), but not treatment, on weight gain over 
the treatment period. Final liver weight was not different between control and treatment 
but liver weight as a percent of body weight was significantly higher in PBDE-treated 
rats compared to control (p < 0.05). 
In order to compare the effect of treatment on liver weight as a function of time, 
data for liver weight and liver weight as a percent of body weight are displayed in Figure 
5 and 6. There was a significant effect of time (p < 0.05) on final liver weight (Figure 5). 
Liver weight as a percent of body weight was higher in the PBDE group with an effect of 
treatment (p < 0.05) and time (p < 0.05) (Figure 6). The slopes of the control and 
treatment trendlines are similar (m = -0.023 and m = -0.022, respectively) indicating the 
effect of treatment was independent of time. 
PEPCK Enzyme Kinetics 
Velocity versus substrate concentration plots for PEPCK (Figures 7 - 9 ) are 
expressed as the mean of 8 experiments ± SEM; plots follow standard Michaelis-Menton 
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kinetics. Each individual velocity vs. substrate curve was fit via SigmaPlot 10 to generate 
Km and Vmax values; data for 8 replicates at each time point and treatment are 
represented as mean ± SEM in Table 3. There was no effect of treatment or time on Km 
values. Vmax values, normalized for protein, were 26%, 44% and 43% lower on average 
in the treatment group, compared to control at 3, 14 and 28 days, respectively, with an 
effect of treatment (p < 0.05) and time (p < 0.05) (Figure 10). The effect of treatment 
was independent of time as the slopes of trendlines for control and treatment are similar 
(m = -0.0003 and m = -0.0004, respectively). Similar results were seen when Vmax 
values were normalized for liver weight (Figure 11). The effect of treatment was 
independent of time, however, the three-fold difference of control and treatment trendline 
slopes (m = -0.0077 and m = -0.0229, respectively) suggested a treatment x time 
interaction (p = 0.11). Vmax values, expressed as total liver PEPCK activity, were 18%, 
34% and 41% lower on average in the treatment group compared to control at 3, 14 and 
28 days, respectively, with an effect of treatment (p < 0.05), time (p < 0.05) and an 
interaction effect (p < 0.05) (Figure 12). 
Blood Measurements 
Fasting glucose, insulin and C-peptide are represented as mean ± SEM in Table 4. 
There was no effect of treatment on any of the values. In order to compare the effect of 
treatment on glucose, insulin and C-peptide as a function of time, data for each value 
displayed in Figure 13, 14 and 15. There was a significant effect of time (p < 0.05) for 
fasting glucose but no significant effect of treatment (Figure 13) and fasting insulin 
(Figure 14). By 28 days, insulin values of the PBDE treatment group were trending to 
lower values compared to control but this apparent interaction was not significant (p = 
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0.17) (Figure 15). This response was mimicked by the C-peptide values; by 28 days, C-
peptide values of the treatment group were trending towards lower values compared to 
control (Figure 15), with an effect of time (p < 0.05) but the interaction effect was not 
significant (p = 0.13). 
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Final body weight (g) 
Control [CI Treatment [Tl 
142.9 ±4.2 141.3 ±1.7 
221.4 ±4.4 213.0 ±5.6 
316.0 ±6.5 305.6 ±3.6 
Weight gain (g) 
C T 
20.0 ±0.8 17.3 ±0.7 
81.9 ±3.1 78.1 ±4.5 
171.3 ±5.5 168.5 ±3.4 
Final liver weight (g) 
C T 
6.38 ±0.21 6.73 ±0.2 
9.71 ±0.31 10.08 ±0.29 
12.33 ±0.38 12.93 ±0.42 
Liver weight as % of BW (%) 
C T 
4.47 ±0.11 4.77 ±0.16 
4.4 ±0.15 4.73 ±0.05 
3.9 ±0.1 4.22 ±0.1 
Table 2: Animal measurements represented as mean ± SEM (n = 8 per group). Final weight and weight gain was similar among 
PBDE-treated group and control, both with an effect of time (p < 0.05). Liver weights were not different between control and PBDE-
treated group, but there was a significant effect of time (p < 0.05). Final liver weight expressed as a percent of body weight was higher 
in PBDE-treated group with an effect of treatment (p < 0.05) and time (p < 0.05). 
Figure 5: Final liver weight at 3, 14 and 28 days of treatment 
n Control • Treatment - - - Linear (Control) ——•— Linear (Treatment) 
Figure 5: Final liver weight measured at 3, 14 and 28 days. There was an effect of time 
(p < 0.05). 
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Figure 6: Liver Weight as Percent of Body Weight at 3,14 and 28 days of treatment 
n Control • Treatment - - - Linear (Control) • Linear (Treatment) 
Figure 6: Liver weight expressed as a percent of body weight. Liver weight as a percent 
of body weight was higher in the PBDE group with an effect of treatment (p < 0.05) and 
time (p < 0.05). 
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Figure 7: 3 day PEPCK, velocity vs. substrate curves, expressed per mg protein and 
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Figure 7: A: PEPCK activity at 3 days, normalized for mg protein for control ( • ) 
animals vs. treatment (•) animals (n = 8, mean ± SEM). B: PEPCK activity at 3 days 
normalized for gram of liver for control ( • ) animals vs. treatment (•) animals (n = 8, 
mean ± SEM). 
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Figure 8: 14 day PEPCK, velocity vs. substrate curves, expressed per mg protein 
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Figure 8: A: PEPCK activity at 14 days, normalized for mg protein for control ( • ) 
animals vs. treatment (•) animals (n = 8, mean ± SEM). B: PEPCK activity at 14 days 
normalized for gram of liver for control ( • ) animals vs. treatment (•) animals (n = 8, 
mean ± SEM). 
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Figure 9: 28 day PEPCK, velocity vs. substrate curves, expressed per mg protein 









• Control - Treatment 
Figure 9: A: PEPCK activity at 28 days, normalized for mg protein for control ( • ) 
animals vs. treatment (•) animals (n = 8, mean ± SEM). B: PEPCK activity at 28 days 
normalized for gram of liver for control ( • ) animals vs. treatment (•) animals (n = 8, 
mean ± SEM). 
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Km [malatel (mM) 
Control rCl Treatment 1T1 
3.89 ±0.77 4.67 ±0.98 
4.63 ±0.42 3.8 + 0.24 
4.17 ±0.5 5.72 ±0.88 
Vmax (umol/min/mg protein) 
C T 
0.023 ±0.003 0.017 + 0.002 
0.016 ±0.001 0.009 ±0.001 
0.014 ±0.001 0.008 ±0.001 
Vmax (umol/min/g liver 
weight) 
C T 
2.2 ±0.18 1.71 ±0.12 
1.92 ±0.11 1.23 ±0.05 
1.99 ±0.09 1.12 ±0.09 
Total PEPCK Activity 
(nmol/min/liver) 
C T 
14.1 ±1.32 11.4 ±0.67 
18.7 ±1.3 12.4 ±0.5 
24.6 ±1.28 14.6 ±1.46 
-p* Table 3: Curve fitting and calculation of PEPCK enzyme kinetics, Km and Vmax, was performed on SigmaPlot 10 shown as mean ± 
SEM at days 3, 14 and 28 (n = 8 per group). Km values were similar between the two groups. Vmax values, regardless of units 
expressed, all had an effect of time (p < 0.05) and an effect of treatment (p < 0.05). Vmax, normalized for g liver weight, had an 
interaction effect approaching significance (p = 0.11). Total PEPCK activity had a significant interaction effect (p < 0.05). 



























D Control • Treatment- - - Linear (Control) Linear (Treatment) 
Figure 10: Vmax values, normalized for protein, were lower in the treatment group with 
an effect of treatment (p < 0.05) and time (p < 0.05). The effect of treatment was 
independent of time as the slopes of trendlines for control (m = -0.0003) and treatment (m 
= - 0.0004) are similar. 
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Figure 11: Vmax values, normalized for liver weight, were lower in the treatment group 
with an effect of treatment (p < 0.05) and time (p < 0.05). The effect of treatment was 
independent of time. The three-fold difference of trendline slopes, control m = -0.0077 
and treatment m = -0.0229, suggests a treatment x time interaction (p = 0.11). 
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Figure 12: Total PEPCK Activity at 3,14 and 28 days of treatment 
n Control • Treatment - - - Linear (Control) — — Linear (Treatment) 
Figure 12: Velocity values, normalized for total PEPCK activity, were lower in the 
treatment group with an effect of treatment (p < 0.05), time (p < 0.05) and an interaction 
effect (p < 0.05). 
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Fasting Glucose (mg/dl) 
C T 
89.33 ±4.23 93.43 ± 6.73 
148.64 ±12.59 153.81 ± 10.06 
184.36 ±7.88 200.47 ±8.17 
Insulin (ng/ml) 
C T 
0.226 ±0.019 0.208 + 0.029 
0.237 ±0.016 0.274 + 0.032 
0.572 ± 0.043 0.434 + 0.075 
C-peptide (pM/0.1 ml) 
C T 
232.4 ±33.19 231.9 ±34.89 
369.9 ±49.58 402.6 ±43.01 
698.3 ±47.32 555.3 ± 74.06 
Table 4: Fasting plasma glucose, insulin and C-peptide are represented as mean ± SEM (N = 8 per group). There was no significant 
effect of treatment on glucose, insulin or C-peptide levels. 
Figure 13: Fasting plasma glucose at 3, 14 and 28 days of treatment 
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D Control • Treatment ——— Linear (Treatment) - - - Linear (Control) 
Figure 13: Plasma glucose following 16-h fast. There was a significant effect of time (p 
< 0.05) for fasting glucose but no significant effect of treatment. 
46 





10 15 20 
Days 
25 
- Linear (Control) 
30 
Figure 14: There was an effect of time (p < 0.05) for insulin levels. The interaction effect 
was not significant (p = 0.17) despite dissimilar slopes (control m = 0.014, treatment m = 
0.0091). 
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Figure 15: There was an effect of time (p < 0.05) for C-peptide. The interaction effect 




This study is the first to investigate the effects of in vivo PBDE treatment on 
hepatic phosphoenolpyruvate carboxykinase (PEPCK) enzyme kinetics. We hypothesized 
that hepatic PEPCK activity would be reduced by in vivo PBDE treatment of rats. Our 
findings support this hypothesis and demonstrate that PBDEs disrupt PEPCK enzyme 
kinetics. 
First, we provide evidence of a reduction in PEPCK Vmax after 3 days of PBDE 
treatment that persisted through 28 days. To our knowledge, four papers exist that have 
investigated the effect of xenobiotic exposure on hepatic PEPCK. Our findings are 
similar to work by Argaud et al. (1991) and Chauvin et al. (1996) who exposed rats to 
100 mg/kg/day of Phenobarbital for two weeks and found a 50% decrease of PEPCK 
Vmax, expressed as umol/min/g liver wet weight. We found a 40% reduction in Vmax 
(umol/min/g liver wet weight) in the treatment group compared to control at 14 days. The 
researchers also found a 30% decrease in Km in treatment rats compared to control 
(Argaud et al. 1991; Chauvin et al. 1996) In contrast to their findings, we found there was 
no disruption of PEPCK Km. This observation in combination with the reduction in 
Vmax, suggests a disruption in transcription and/or translation of the PEPCK gene or 
protein, respectively. This would need to be confirmed by determining protein levels of 
PEPCK following PBDE treatment. Our findings are also consistent with work by 
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Viluksela et al. (1999) who exposed rats to a range of 50-9600 u.g/kg of TCDD for 10 
days and found a maximum Vmax reduction of 50% with the highest dose in male rats 
compared to control (Viluksela et al. 1999). Vijayan et al. (2006) also found a 66% 
reduction of PEPCK activity in the treatment group compared to control Anadromous 
arctic char following exposure to 100 mg/kg of Aroclor 1254 (Vijayan et al. 2006). 
Second, we examined the physiological effects of PBDE treatment on glucose 
metabolism by analyzing fasting glucose, insulin and C-peptide values. Despite the 
decrease in PEPCK Vmax, we found fasting glucose was not impacted by PBDE 
treatment. This is consistent with the work of She et al. (2003) using liver PEPCK-
knockout mice. The liver PEPCK-knockout mice maintained fasting blood glucose levels 
that were similar or even higher than control. She et al. (2003) suggest that this 
maintenance of blood glucose levels could be attributed to an up-regulation of 
gluconeogenesis in extrahepatic tissues such as the kidney (She et al. 2003). Work by 
Hakimi et al. (2005) confirms the importance of PEPCK in the kidney. Hepatic and 
kidney PEPCK knockout mice did not gain weight one day after birth, had 60% lower 
glucose levels, twice the level of triglycerides in the blood and liver and three times the 
level of ketone bodies compared to control (Hakimi et al. 2005). 
Our findings are in contrast to Viluksela et al. (1999) who saw a decrease in 
plasma glucose of treatment rats exposed to TCDD compared to control and Vijayan et 
al. (2006) who, in addition to a reduction of PEPCK Vmax, also found a 55% reduction 
of plasma glucose in fish following exposure to PCB. These discrepancies are most likely 
due to using different species models (fish vs. rat), different chemicals (TCDD or PCB 
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vs. PBDE), different dosages (9600 u,g/kg TCDD or 100 mg/kg PCB vs. 14 mg/kg DE-
71) and different time periods (10 days or 4 months vs. 28 days). 
Unpublished work done in our lab found insulin was 30% lower after 28 days of 
PBDE treatment compared to control, although this was not statistically significant (p = 
0.075) (Allgood 2009). Allgood used the same dose of DE-71 for the same length of time 
and the same species of Wistar rat. Although the treatment effect was also not significant 
in our work, we found a 24% decrease in insulin at 28 days. It is possible that this 
decrease could be exacerbated by treatment time. 
There are several possible mechanisms by which PBDE exposure could affect 
PEPCK activity. First, it is known that PBDE exposure decreases thyroid hormone, T4, in 
rats (Hallgren and Darnerud 2002; Zhou et al. 2001; Zhou et al. 2002). Thyroid hormone 
normally diffuses through the nucleus and binds to its nuclear receptor (NR). The NR-
thyroid hormone complex will then bind to the thyroid response element on the PEPCK 
gene promoter (Yabaluri and Bashyam 2010). Therefore, PEPCK gene promotion could 
be reduced due to low levels of thyroid hormone. Another possible mechanism is via 
another nuclear receptor, pregnane X receptor (PXR). It is known that PBDEs are a 
ligand to PXR (Fery et al. 2009; Pacyniak et al. 2007). It is also known that activated 
PXR results in a reduced gene expression of PEPCK (Bhalla et al. 2004; Zhou et al. 
2006) via direct interaction with the forkhead transcription factor, FOXOl, a PEPCK 
gene activator (Kodama et al. 2004). Therefore, a plausible mechanism of action is that 
PBDE exposure activates PXR, inhibiting FOXOl from binding to the response element 
on the PEPCK gene promoter, causing a reduction in PEPCK gene and, ultimately, a 
reduction in PEPCK activity. This mechanism, however, requires validation. 
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The decreased activity of PEPCK combined with unaffected levels of glucose and 
a tendency toward lower levels of insulin following exposure to PBDEs suggests mild 
glucose metabolism disruption in rats. There is very limited evidence that this disruption 
occurs in humans. In 2008, a cross-sectional study using NHANES data examined the 
correlation between diabetes and serum levels of brominated flame retardant. There was a 
significant positive correlation between polybrominated biphenyl-153 (PBB-153) and 
diabetes (defined as fasting glucose levels of >126 mg/dL and non-fasting glucose levels 
of >200 mg/dL) and a monotonic association between PBDE-153 and diabetes (Lim et 
al. 2008). Correlation does not mean causation, however, and further investigation is 
warranted to determine if environmental chemicals are contributing to the diabetes 
epidemic occurring in the United States. 
Our findings, in combination with existing literature, confirm that exposure to 
xenobiotics such as PB, PCB and PBDEs affect glucose metabolism by decreasing 
PEPCK activity and, in some cases, altering plasma glucose and insulin levels. Future 
work should focus on the mechanism of this disruption by examining protein and mRNA 
expression of PEPCK following PBDE exposure to determine if the disruption occurs at 
the transcriptional and/or translational level. 
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APPENDIX A 





















CYP1A CYP3A CYP2B 
This series of experiments examined the effect of in vivo PBDE exposure of rats 
on cytochrome P450 (CYP) enzyme activity. In summer of 2010, sixteen male Wistar 
rats were gavaged with two types of treatment: corn oil or corn oil with 14 mg/kg PBDE 
for 28 days. They has access to food from 8 AM to 5 PM and water ad libitum. 
Approximately 1.5 g of liver from animals were sent to North Carolina for CYP activity 
analysis. CYP activity was measured via a fluorometric assay as described previously 
(Szabo et al. 2009). CYP activity was significantly induced by treatment compared to 
control (* p < 0.05 compared to control). CYPl A was induced in the treatment group by 
95%, CYP3A by 99% and CYP2B by 94% on average compared to control. 
These data confirm that PBDE exposure induces hepatic CYP activity in rats. 
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